The COVID-19 inactivated vaccine researched and developed by China’s Wuhan Institute of Biological Products makes sound result. [Photo provided to Gwadar Pro]
BEIJING, June 17 (Gwadar Pro) – All subjects of the coronavirus vaccine researched and developed by China’s Wuhan Institute of Biological Products have developed antibodies, with a 100 percent positive conversion rate.
According to China’s State-owned Assets Supervision and Administration Commission (SASAC), the meeting for the blind review and the unblinding of the Phase I and II clinical trial results of COVID-19 inactivated vaccine were held in China’s Beijing and Henan Province synchronously on Tuesday.
The unblinding shows that the safety of the vaccine is sound, without any case of adverse reaction. All the 1,120 subjects who had got two injections have produced high titer of antibody, with the neutralizing antibody positive rate of 100 percent.
Meanwhile, China National Biotec Group, the parent company of Wuhan Institute of Biological Products, is actively promoting the Phase Ⅲ clinical cooperation overseas, and has confirmed the intention of cooperation with enterprises and institutions in several countries.
It is learnt that the coronavirus vaccine may appear on the market at the end of 2020 or the beginning of 2021, according to SASAC. The workshop has been making the final preparation for the production of the vaccine since May 30, 2020.
China National Biotec Group belongs to China National Pharmaceutical Group Co., Ltd.(Sinopharm), a large healthcare group. Sinopharm has a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.